23 results
Thumbnail

D1.16 - Molecular sensitization profiles in house dust mite allergic patients from Valencian Community

Thumbnail

D1.18 - Comparative Analysis of Nasal Secretions and Serum Biomarkers in House Dust Mite Allergy: Correlation with Symptoms and Skin Prick Test Results

Thumbnail

D1.19 - Contribution of Panallergens to Edible Insect Reactivity in Mite-Sensitized Individuals

Thumbnail

D1.20 - Progesterone-Induced Urticaria: Diagnostic and Therapeutic Approach

Thumbnail

D1.22 - Molecular Allergen Sensitization Patterns in Cat, Dog and Horse Allergies in Children

Thumbnail

D1.23 - Unrestricted Potential: The Role of AMS in Tackling Allergy Labels

Thumbnail

D1.24 - Towards risk assessment of peanut sensitised patients based on statistical modelling of 32,500 IgE-macroarray test results

Thumbnail

D1.25 - Clinical Characteristics of Chronic Urticaria in Adults Under 45 Years Old with Vitamin D Insufficiency

Thumbnail

D1.428 - Fungal Microbiome Diversity in Urban Forest Decreases Asthma and Allergic Inflammation

Thumbnail

D1.431 - Associations of the composition of intestinal microbiota with the initial manifestations of IgE-mediated food allergy in children 6-12 months old

Thumbnail

D1.433 - The effect of preventive administration of probiotic strain E. coli 083:H24:K31 on selected immune characteristics of eight-year-old children

Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience

Thumbnail

D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab

Thumbnail

D2.359 - Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age